Lavestra Hct (Losartan Potassium, Hydrochlorothiazide)

Losartan potassium blocks AT1 receptors for angiotensin II, preventing the hormone from causing blood‑vessel constriction and aldosterone release. This leads to vasodilation and reduced sodium‑water retention, contributing to lower systemic blood pressure when used together with the diuretic component.

The specific dose of Lavestra Hct is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and other clinical factors. Healthcare professionals adjust the regimen to achieve optimal blood‑pressure control while minimizing adverse effects.

Safety of Lavestra Hct in pregnancy or lactation has not been established. It should be avoided unless the potential benefit justifies the risk, and only under direct medical supervision. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy agents, Lavestra Hct offers dual‑action blood‑pressure control through both receptor blockade and diuresis, often achieving target pressures with a single pill. This can improve adherence versus taking separate losartan and thiazide tablets, though individual response and tolerability vary.

Lavestra Hct tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Lavestra Hct is taken orally, usually once daily, with or without food as directed by a healthcare professional. Swallow the tablet whole with a full glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, hyperkalemia, and angioedema. Patients should be monitored for sudden drops in blood pressure, changes in renal function, electrolyte imbalances, and any signs of swelling of the face, lips, or throat, which require immediate medical attention.

Lavestra Hct is contraindicated in patients with known hypersensitivity to losartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, anuria, or those taking potassium‑sparing agents that could precipitate dangerous electrolyte disturbances.